CSIMarket


F star Therapeutics Inc   (FSTX)
Other Ticker:  
 


 

F star Therapeutics Inc

FSTX's Financial Statements and Analysis



F star Therapeutics Inc increased third quarter of 2022 net loss per share of $-0.84 compare to net loss per share of $-0.52 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.88 realized in previous quarter.


third quarter of 2022
Earnings Per Share Revenues
$ -0.84 $  1 Mill
$-0.32     Unch.     +49.8 %



F Star Therapeutics Inc 's Revenue rose by 49.8 % in third quarter of 2022 (Sep 30 2022) year on year, to $1 million and advanced by sequentially.


F Star Therapeutics Inc is

More on FSTX's Income Statement



F Star Therapeutics Inc 's in thethird quarter of 2022 recorded net loss of $-18.407 million, an increase from net loss of $-10.791 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-18.994 million realized in previous quarter.

More on FSTX's Growth

F Star Therapeutics Inc Inventories
In Sep 30 2022 company's net cash and cash equivalents decreased by $-17 million

More on FSTX's Cash flow Statement


F star Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period F star Therapeutics Inc payed $ -1.73 cash per share, on a free-cash flow basis .

Book value fell by -21.55 % sequentially to $2.61 per share, -35.13% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 1.22 per share from $ 1.85.

Company issued 0.28 million shares or 1.31 % in Sep 30 2022.


More on FSTX's Dividends

 Market Capitalization (Millions) 156
 Shares Outstanding (Millions) 22
 Total Debt (Millions $) 10
 Revenue (TTM) (Millions $) 21
 Net Income (TTM) (Millions $) -44
 Cash Flow (TTM) (Millions $) -35
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 56




F star Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period F star Therapeutics Inc had negative $ -1.73 cash flow per share, on a free-cash flow basis .

Book value fell by -21.55 % sequentially to $2.61 per share, -35.13% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 1.22 per share from $ 1.85.

Company issued 0.28 million shares or 1.31 % in Sep 30 2022.


More on FSTX's Balance Sheets

 Market Capitalization (Millions) 156
 Shares Outstanding (Millions) 22
 Total Debt (Millions $) 10
 Revenue (TTM) (Millions $) 21
 Net Income (TTM) (Millions $) -44
 Cash Flow (TTM) (Millions $) -35
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 56
   



Date modified: 2022-11-13T01:14:33+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com